TickerFacts.

Company research / REGN

Regeneron Pharmaceuticals, Inc. (REGN)

Build a valuation ↗↓ Download CSV

SEC name REGENERON PHARMACEUTICALS, INC. · CIK 0000872589 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated NY
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Regeneron Pharmaceuticals, Inc. reported revenue of $14.34B. Revenue grew 1.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $15.53B.

Key ratios (year ended 2025-12-31)

24.9%
Operating margin
31.4%
Net margin
14.4%
Return on year-end equity
1.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-15

Headquarters locality: Eastview · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$15.53B$14.34B$14.20B$13.12B$12.17B$16.07B$8.50B$6.56B$5.15B$5.87B$4.86B
Cost of Revenuen/an/an/an/an/an/an/a$402.80M$237.50Mn/an/a
Gross Profit (computed)n/an/an/an/an/an/an/a$6.15Bn/an/an/a
R&D Expense$6.28B$5.85B$5.13B$4.44B$3.59B$2.86B$2.65B$2.45B$1.47B$2.08B$2.05B
Operating Income$3.84B$3.58B$3.99B$4.05B$4.74B$8.95B$3.58B$2.21B$2.53B$2.08B$1.33B
Depreciation & Amortization$528.60M$543.70M$482.90M$421.00M$341.40M$286.20M$235.90M$210.30M$148.20M$145.50M$104.70M
EBITDA$4.37B$4.12B$4.47B$4.47B$5.08B$9.23B$3.81B$2.42B$2.68B$2.23B$1.44B
Net Income$4.33B$4.50B$4.41B$3.95B$4.34B$8.08B$3.51B$2.12B$2.44B$1.20B$895.50M
EPS (Diluted)n/a$41.48$38.34$34.77$38.22$71.97$30.52$18.46$21.29$10.34$7.70
Total Assets$41.73B$40.56B$37.76B$33.08B$29.21B$25.43B$17.16B$14.81B$11.73B$8.76B$6.97B
Total Liabilities$10.02B$9.30B$8.41B$7.11B$6.55B$6.67B$6.14B$3.72B$2.98B$2.62B$2.52B
Shareholders' Equity$31.71B$31.26B$29.35B$25.97B$22.66B$18.77B$11.03B$11.09B$8.76B$6.14B$4.45B
Cash & Equivalents$2.46B$3.12B$2.49B$2.73B$3.11B$2.89B$2.19B$1.62B$1.47B$812.70M$535.20M
Operating Cash Flow$4.68B$4.98B$4.42B$4.59B$5.01B$7.08B$2.62B$2.43B$2.20B$1.31B$1.49B
Capital Expenditures$920.90M$898.40M$755.90M$718.60M$590.10M$551.90M$614.60M$429.60M$383.10M$272.60M$511.90M
Free Cash Flow$3.76B$4.08B$3.66B$3.88B$4.42B$6.53B$2.00B$2.00B$1.81B$1.03B$974.00M
Share Repurchases$3.30B$3.44B$2.60B$2.23B$2.08B$1.65B$5.85B$275.90M$4.40M$0$0
Dividends Paid$378.50M$370.30M$0$0n/an/an/an/an/an/an/a
Weighted Average Diluted Sharesn/a108.60M115.10M113.70M113.50M112.20M115.10M114.60M114.80M115.90M116.30M
EPS (Basic)n/a$43.07$40.90$37.05$40.51$76.40$32.65$19.38$22.65$11.27$8.55

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView